PCSK9 and metabolic dysfunction-associated steatotic liver disease: More novel ground-breaking treatment targets such as proprotein convertase subtilisin/kexin type 9 (PCSK9) may be forthcoming, and a breakthrough in NAFLD and/or CVD prevention and reduction will be the next important milestone.